We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+44.2%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.62B
AUM Growth
+$469M
(+22%)
Cap. Flow
-$157M
Cap. Flow
% of AUM
-5.99%
Top 10 Holdings %
Top 10 Hldgs %
40.11%
Holding
87
New
14
Increased
8
Reduced
51
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$147M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$72.5M |
| 3 |
Arcturus Therapeutics
ARCT
|
+$18.5M |
| 4 |
Pliant Therapeutics
PLRX
|
+$16.2M |
| 5 |
uniQure
QURE
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$64.1M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$33.9M |
| 3 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$31.5M |
| 4 |
XLRN
Acceleron Pharma
XLRN
|
+$21.7M |
| 5 |
IMVTU
Immunovant, Inc. Units
IMVTU
|
+$19.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Arcturus Therapeutics
ARCT
$173M
| $37.4M | 1.43% |
800,000
+537,963
| +205% | +$18.5M |
|
27
Rocket Pharmaceuticals
RCKT
$387M
| $30.7M | 1.17% |
1,468,550
-100,000
| -6% | -$1.8M |
|
28
CRISPR Therapeutics
CRSP
$4.99B
| $29.4M | 1.12% |
400,000
-230,400
| -37% | -$13.5M |
|
29
Axsome Therapeutics
AXSM
$10.8B
| $28.8M | 1.1% |
350,000
-150,000
| -30% | -$11.5M |
|
|
BPMC
30
DELISTED
Blueprint Medicines
BPMC
| $27.3M | 1.04% |
350,000
-100,000
| -22% | -$6.76M |
|
31
Ascendis Pharma A/S
ASND
$16.4B
| $25.9M | 0.99% |
175,000
-75,000
| -30% | -$10.3M |
|
|
AXNX
32
DELISTED
Axonics, Inc. Common Stock
AXNX
| $25.3M | 0.97% |
720,397
-79,603
| -10% | -$2.74M |
|
33
Twist Bioscience
TWST
$6.84B
| $25M | 0.96% |
552,849
-134,300
| -20% | -$4.82M |
|
|
IGMS
34
DELISTED
IGM Biosciences
IGMS
| $24.8M | 0.95% |
340,146
-85,958
| -20% | -$5.22M |
|
|
TCDA
35
DELISTED
Tricida, Inc. Common Stock
TCDA
| $24M | 0.91% |
872,137
-5,838
| -0.7% | -$159K |
|
36
Cabaletta Bio
CABA
$450M
| $23.5M | 0.9% |
2,105,844
-2
| -0% | -$15 |
|
|
STSA
37
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $23M | 0.88% |
798,905
-9,477
| -1% | -$219K |
|
38
Beam Therapeutics
BEAM
$2.81B
| $22M | 0.84% |
796,429
| – | – |
|
|
QTNT
39
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $21.5M | 0.82% |
72,510
-6,528
| -8% | -$1.88M |
|
40
Zai Lab
ZLAB
$2.36B
| $20.5M | 0.78% |
250,000
-39,092
| -14% | -$2.64M |
|
|
41
uniQure
QURE
$3.15B
| $20M | 0.76% |
444,157
+194,157
| +78% | +$11.5M |
|
42
Zymeworks
ZYME
$1.7B
| $19.8M | 0.76% |
550,000
-150,000
| -21% | -$5.52M |
|
43
AnaptysBio
ANAB
$1.62B
| $19.8M | 0.76% |
885,838
-222,062
| -20% | -$4.06M |
|
|
LKFT
44
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
| $19.5M | 0.74% |
99,075
+472
| +0.5% | +$97.8K |
|
|
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $19M | 0.73% |
318,914
-31,086
| -9% | -$1.66M |
|
|
46
Pliant Therapeutics
PLRX
$65M
| $18.8M | 0.72% |
+611,409
| New | +$16.2M |
|
47
Sarepta Therapeutics
SRPT
$1.77B
| $17.6M | 0.67% |
110,000
-40,000
| -27% | -$5.44M |
|
48
argenx
ARGX
$54.8B
| $15.8M | 0.6% |
70,000
-10,000
| -13% | -$1.78M |
|
49
NextCure
NXTC
$22.7M
| $14.9M | 0.57% |
57,831
-4,119
| -7% | -$1.57M |
|
|
AKRO
50
DELISTED
Akero Therapeutics
AKRO
| $14.8M | 0.56% |
592,539
-50,000
| -8% | -$1.14M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q2 2020 Portfolio in Review
As of Q2 2020, Cormorant Asset Management held 87 positions worth $2.62B, up 22% from $2.15B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Cormorant Asset Management withdrew a net $157M in Q2 2020, closing 6 positions and reducing 51 holdings. Its most notable exit was Constellation Pharmaceuticals, Inc., an estimated $64.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 76% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Forma Therapeutics Holdings, Inc. Common Stock worth $153M.
- Cormorant Asset Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 3,379,373 shares worth $153M.
- Cormorant Asset Management added most to Arcturus Therapeutics in Q2 2020, an estimated $18.5M increase.
- Cormorant Asset Management's biggest Q2 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $33.9M.
- Cormorant Asset Management fully exited Constellation Pharmaceuticals, Inc. in Q2 2020, selling an estimated $64.1M.
- Cormorant Asset Management's ten largest holdings make up 40% of its $2.62B portfolio in Q2 2020.
- Cormorant Asset Management opened 14 new positions and closed 6 in Q2 2020.
- Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.62B.
Based on Cormorant Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.